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1 Biological Dynamics, Inc., San Diego, CA, United States, 2 Departments of Translational Molecular Medicine and Sequence
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The power of personalized medicine is based on a deep understanding of cellular
and molecular processes underlying disease pathogenesis. Accurately characterizing
and analyzing connections between these processes is dependent on our ability to
access multiple classes of biomarkers (DNA, RNA, and proteins)—ideally, in a minimally
processed state. Here, we characterize a biomarker isolation platform that enables
simultaneous isolation and on-chip detection of cell-free DNA (cfDNA), extracellular
vesicle RNA (EV-RNA), and EV-associated proteins in unprocessed biological fluids
using AC Electrokinetics (ACE). Human biofluid samples were flowed over the ACE
microelectrode array (ACE chip) on the Verita platform while an electrical signal was
applied, inducing a field that reversibly captured biomarkers onto the microelectrode
array. Isolated cfDNA, EV-RNA, and EV-associated proteins were visualized directly on
the chip using DNA and RNA specific dyes or antigen-specific, directly conjugated
antibodies (CD63, TSG101, PD-L1, GPC-1), respectively. Isolated material was also
eluted off the chip and analyzed downstream by multiple methods, including PCR,
RT-PCR, next-generation sequencing (NGS), capillary electrophoresis, and nanoparticle
size characterization. The detection workflow confirmed the capture of cfDNA, EV-RNA,
and EV-associated proteins from human biofluids on the ACE chip. Tumor specific
variants and the mRNAs of housekeeping gene PGK1 were detected in cfDNA and
RNA isolated directly from chips in PCR, NGS, and RT-PCR assays, demonstrating that
high-quality material can be isolated from donor samples using the isolation workflow.
Detection of the luminal membrane protein TSG101 with antibodies depended on
membrane permeabilization, consistent with the presence of vesicles on the chip.
Protein, morphological, and size characterization revealed that these vesicles had the
characteristics of EVs. The results demonstrated that unprocessed cfDNA, EV-RNA,
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and EV-associated proteins can be isolated and simultaneously fluorescently analyzed
on the ACE chip. The compatibility with established downstream technologies may also
allow the use of the platform as a sample preparation method for workflows that could
benefit from access to unprocessed exosomal, genomic, and proteomic biomarkers.
Keywords: biomarkers, cell-free DNA, extracellular vesicles, plasma, personalized medicine, multi-omics, liquid
biopsy, AC electrokinetics
INTRODUCTION
The goal of personalized medicine is to individualize care
pathways, tailor screening, treatment, disease monitoring, and
prevention recommendations to one’s genomic and proteomic
makeup (Crowley et al., 2013; DiazJr., and Bardelli, 2014; Lewis
et al., 2015; Cohen et al., 2017; De Rubis et al., 2019). Scientific
discoveries that drive our understanding of an individual’s
cellular and molecular processes rely on a combination of
insights based on genomic and proteomic technologies. These
often require biomarker-specific purification workflows (DNA,
RNA, and proteins) that are performed on multiple isolation
platforms, use highly pre-processed biological material, and
lengthy analytical procedures that limit routine clinical use
(Gold et al., 2015; Volik et al., 2016; Cohen et al., 2018;
Aggarwal et al., 2019).
Today, comprehensive profiling of a single blood sample
could require the use of three distinct technologies, each using
a separate isolation method to analyze one single class of
biomarkers: circulating cell-free tumor DNA (ctDNA), tumor
RNA, and proteins (Lo Cicero et al., 2015; Möhrmann et al.,
2018). With the incorporation of new classes of biomarkers,
such as extracellular vesicles (EVs) and their dedicated isolation
workflows, analytical toolsets continue to grow in size and
complexity, hampering translation to routine testing (Théry et al.,
2018). Thus, an important step toward accessible personalized
medicine could be the development of a workflow capable of
simultaneous isolation and analysis of DNA, RNA, and EV-
associated protein biomarkers in minimally processed samples
(Vaidyanathan et al., 2018).
The work presented here describes the characterization of a
novel isolation platform, Verita (Biological Dynamics, CA), to
perform rapid and simultaneous isolation of the three different
types of biomarkers directly from blood-based matrices using an
AC Electrokinetics (ACE) powered microelectrode array (ACE
chip). The ACE field essentially functions as a band-pass filter;
the field’s properties could be altered to enable enrichment
of isolated biomaterial for biomarkers in a specific size range
(Sonnenberg et al., 2013; Ibsen et al., 2015). During the isolation
phase, the ACE field is generated on the chip using a specific
voltage/frequency algorithm and microelectrode array design
(Figure 1 and Supplementary Material). The field creates dipole
on affected particles and directs them to specific locations on a
microelectrode array (Oh et al., 2009; Krishnan et al., 2011; Ibsen
et al., 2017; Turner et al., 2018).
The above principle is also applied for the workflows
that analyze biological material that is enriched for cell-free
DNA (cfDNA) and EVs bearing DNA, RNA, and proteins in
unprocessed and minimally processed samples. Following the
capture, biomarkers of interest are characterized either on the
chip using fluorescent detection or eluted off the chip for
secondary analysis with technologies such as PCR and NGS.
On-chip detection of cancer biomarkers using the ACE method,
as well as in-situ and downstream analysis of the captured
biomarkers, have been demonstrated by multiple research groups
(Sonnenberg et al., 2014; Manouchehri et al., 2016; Ibsen et al.,
2017; Lewis et al., 2018, 2019, 2020). The objective of this
work was to evaluate the feasibility of using a single-chip,




The prospective collection of human blood samples from
cancer donors and healthy controls was approved through an
Institutional Review Board and performed under Western IRB
approved protocols. The samples and donor information were
handled according to the Declaration of Helsinki. Written,
informed consent for research use was obtained from individuals
at participating institutions.
Alternating Current Electrokinetic
Microelectrode Array Chip (ACE Chip)
The ACE chip used on the Verita platform is a
microelectromechanical systems (MEMS) fabricated device
with dimensions of 14 mm × 52 mm organized into an
8-array configuration, with each array consisting of ∼1,000
platinum circular electrodes coated with a hydrogel. For isolation
workflow, minor changes in the chamber design were used
to merge eight individual array chambers (used for detection
workflow) into one single chamber. A basic schematic of ACE
chip construction and a description of the principles of AC
electrokinetic isolation of particles are shown in Supplementary
Figure S1. The ACE chip is optimized to work with physiological
solutions (conductivities 10–15 mS/cm). A schematic of the
Verita platform with the detection and isolation workflows is
shown in Figure 2.
Reagents
NoLimits DNA fragments, YOYO-1 Iodide, and SYTO
RNASelect Green Fluorescent Cell Stain were purchased
from Thermo Fisher Scientific (Waltham, MA, United States).
Human genomic DNA (gDNA) was purchased from Promega
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FIGURE 1 | The ExoVerita system consists of an instrument and a consumable cartridge that encases a microfluidic chip. The instrument (left) controls and
monitors AC Electrokinetics (ACE) run parameters. The chip (right) is split into eight arrays, with each array housing approximately 1,000 circular platinum electrodes
that transmit capture signal. For on-chip detection experiments, one array is used per each sample; for isolation experiments, to maximize capture yield, all eight
arrays are used per each sample.
FIGURE 2 | Verita Platform detection and isolation workflows. To detect biomarkers, antibodies, or dyes are incubated with samples, followed by ACE capture,
washing, and imaging. Additional washes and antibody incubations can be performed for indirect immunofluorescence (Detection workflow, top). To isolate
biomarkers, ACE capture is performed, followed by washing with an elution buffer, biomarker release from the electrodes, and collection of released materials
(Isolation workflow, bottom).
Corporation (Madison, WI, United States). Endotoxin-free
Dulbecco’s phosphate buffered saline (PBS), molecular grade
water, and saponin detergent were obtained from EMD Millipore
(Burlington, MA, United States). Tris-EDTA, nuclease-free water
was obtained from VWR (Radnor, PA, United States). UltraCruz
Blocking Agent and antibodies directed against CD63 (clone
MX-49.129.5), TSG101 (clone c-2), and glypican-1 (GPC-1; clone
4D1) were obtained from Santa Cruz Biotechnology (Dallas,
TX, United States). Directly conjugated anti-programmed death
ligand-1 antibody (PD-L1; clone 2746) was obtained from
Biotium (Fremont, CA, United States). Fluorophore conjugated,
affinity-purified F(ab)2 goat anti-mouse IgG was purchased
from Jackson ImmunoResearch Laboratories (West Grove, PA,
United States). K2EDTA plasma used for spiked gDNA and EV
experiments was purchased from Innovative Research (Novi, MI,
United States). Quantitative multiplex reference standard gDNA
(HD701) was purchased from Horizon Discovery (Cambridge,
United Kingdom). Cerebrospinal fluid was obtained from
Gemini Bio-Products (West Sacramento, CA, United States).
Plasma Preparation
Whole blood from cancer donors was prospectively collected in
K2EDTA (Vacutainer Plastic Plus EDTA Blood Collection Tubes,
Becton Dickinson, Franklin Lakes, NJ, United States) tubes and
processed to plasma within 4 h of collection. The blood was
processed into plasma by centrifuging blood tubes at 300 × g for
10 min at 23◦C, followed by the transfer of the supernatant to a
new conical tube and centrifuging again at 4,300 × g for 20 min
at 23◦C. Retrospectively collected cancer plasma specimens were
also procured from BioIVT (Westbury, NY, United States) and
Discovery Life Sciences (Los Osos, CA, United States), and stored
at -80◦C. Retrospective samples were thawed and spun at 4,300
g for 20 min at 23◦C to remove any remaining cell debris or
aggregated proteins immediately prior isolation on the ACE
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chip. Clinical characteristics of cancer donors are provided in
Supplementary Table S1.
Fluorescence Microscopy
Images were captured using a monochrome CMOS camera
(FLIR, Wilsonville, OR, United States), and a BX41 microscope
equipped with a Uplan FLX 4X objective (Olympus, Tokyo,
Japan. Illumination was provided via a mercury vapor short
arc lamp (Excelitas, Covina, CA, United States), and filtered
using appropriate fluorescence bandpass filters and dichroic
beamsplitters (Semrock, Rochester, NY, United States). All
images were acquired with a 2,000 ms exposure at two different
gains, one at zero and another at 24. For display purposes, images
were loaded into Image J2 software (Rueden et al., 2017) and
normalized to the same scale using the set display range feature.
Co-detection of EV-Associated Proteins
and Nucleic Acids
For simultaneous detection of cfDNA and exosomal proteins
plasma samples prepared as described above were diluted 1:1
with 0.5 × PBS (undiluted samples were used for cfDNA-only
detection experiments in Supplementary Figure S2). Either
nucleic acid dyes (YOYO-1 or SYTO RNASelect) or primary
antibodies directed against biomarker proteins of interest,
together with a fluorophore-conjugated secondary antibody,
were added directly to the diluted plasma samples and incubated
for 15 min at 37◦C [CD63, 1:400; PD-L1, 1:200; GPC-1, 1:1,000;
Alexa Fluor 488-F(ab’)2 Goat anti-Mouse IgG, 1:750]. Samples
were loaded onto the ACE chip and a signal of 7 Vpp and
14 kHz was applied to the chip for 10 min. Following capture,
unbound material was washed off the chip with TE buffer for an
additional 5 min at 10 µL/min with the same signal parameters.
Chips were analyzed for the presence of each of the EV-associated
proteins and cfDNA via fluorescence microscopy followed by
image display and normalization using ImageJ2.
Luminal protein TSG101 visualization experiments used the
following modified protocol. Unlabeled plasma samples were
loaded onto the ACE chip, and a signal of 10 Vpp and 14 kHz
was applied for 14 min. Following a TE buffer wash of 10 min at 3
µL/min, the ACE signal was turned off, and 0.1% saponin diluted
into 1X PBS was flowed through the chip at 3 µL/min for 10 min.
Antibody against TSG101 was diluted into UltraCruz Blocking
Reagent and flowed through the ACE chip at 3 µL/min for
10 min. The fluid flow was then stopped, and the chip incubated
for an additional 60 min at room temperature. To remove
unbound antibodies, the ACE chip was washed with 1X PBS at 3
µL/min for 10 min. Fluorophore-conjugated secondary antibody
was then flowed onto the chip and incubated for an additional
60 min, washed with 1X PBS, then analyzed as described above.
Capture and Isolation of Cell-Free DNA
Using the ACE Chip
A plasma sample was loaded into the ACE chip at a rate of
10 µL/min for 4 min to fill the flow cell. Once the flow cell
was filled, the sample flowed through the chip at 3 µL/min
for 40 min while an ACE signal of 8.5 Vpp and 14 kHz was
applied for a total of 120µL processed on the chip. With the ACE
signal still active, the flow cell was washed with Wash Solution
1 (Biological Dynamics) for 12 min at 3 µL/min followed by
Elution Buffer 2 (Biological Dynamics) for 12 min at 3 µL/min.
The electrical signal was turned off, and the chip was incubated
at room temperature for 20 min to allow the cfDNA to detach
from the electrodes. Approximately 35 µL of purified sample was
removed from the flow cell.
Capture and Isolation of EVs Using the
ACE Chip
ACE chips were initially prepared, and plasma samples were
loaded as described above. After the flow cell was filled, an
electrical signal of 7 Vpp, 14 kHz was applied for 40 min while
flowing plasma through the cell at 3 µL/min. The flow cell was
washed with Elution Buffer 1 (Biological Dynamics) for 30 min
at 3 µL/min. The electrical signal was turned off, and the chip
incubated at room temperature for 20 min to allow the EVs to
detach from the electrodes. Approximately 35 µL of purified
sample was then removed from the flow cell.
Polymerase Chain Reaction
PCR and RT-PCR were performed on isolated samples using
the ViiA7 Real-Time PCR System (Thermo Fisher Scientific).
DNA amplification was performed in a 20 µL reaction
containing 10 µL of the Luna Universal qPCR Master Mix
(New England BioLabs, Ipswich, MA, United States), 4 µL of
nuclease-free water, 5 µL of DNA template or isolated sample
directly following isolation, and 1 µL of primer/probe mix
for mutation detection. The PCR reaction conditions were as
follows: initial denaturation for 1 min at 95◦C, then 45 cycles
of denaturation (95◦C for 15 s), and extension (60◦C for 30 s).
Sequences of the primers and probes for the ACTB gene were
the following: Forward: 5’-AAG ACA GTG TTG TGG GTG
TAG-3’; Reverse: 5’-AGACCTACTGTGCACCTACT-3’; Probe:
5’-VIC-TGTAAAGCGGCCTTGGAGTGTGTA-MGBNFQ-3’.
Primers and probe for KRAS G12D mutation detection were
purchased from Thermo Fisher Scientific (KRAS_521_mu, Assay
ID: Hs000000051_rm, Cat. # A44177).
RNA amplification using RT-PCR was a one-step process
performed in a 20 µL reaction containing 10 µL of the one-step
reaction mix from the Luna Universal Probe One-Step RT-qPCR
Kit (New England BioLabs, United States), 1 µL of Luna Warm
Start RT Enzyme mix, 1 µL of nuclease free water, 7 µL of RNA
template or isolated sample and 1 µL of the primer/probe mix
for PGK1 (Assay ID: Hs99999906_m1, Cat. # 4351370, Thermo
Fisher Scientific). The amplification reaction conditions were
as follows: reverse transcription for 10 min at 55◦C, followed
by initial denaturation for 1 min at 95◦C, then 45 cycles of
denaturation (95◦C for 15 s) and extension (60◦C for 30 s). Total
RNA Control (Human, Cat. #4307281, Thermo Fisher Scientific)
was used as a positive control.
Next-Generation Sequencing
NGS was performed on isolated samples using an Illumina
MiSeq sequencer (Illumina, San Diego, CA, United States)
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and the AmpliSeq for Illumina Cancer HotSpot Panel v2 for
target amplification of regions that are commonly mutated
in human cancer genes as well as the AmpliSeq Library
PLUS and AmpliSeq UD Indexes for library preparation and
index ligation. The library was prepared using 12 µL of
sample, according to manufacturer’s protocols. Sequencing was
performed in a 2 × 151 bp read fashion using the MiSeq
Reagent Kit v2 (300-cycles) with 5% PhiX as control. FASTQ
files were analyzed using the DNA Amplicon app version
2.1.1 (Illumina) with options selected for BWA aligner, RefSeq
annotation, indel realignment, and variant caller depth filter
for 100×.
EV Isolation From Cell Culture Media
EVs were isolated from the cell culture supernatants of the
cell lines from ATCC (Manassas, VA), MDA-MB-231 (ATCC
HTB-26), and AsPC-1 (ATCC CRL-1682) by centrifugation
at 3,000 RCF for 20 min followed by centrifugation at
100,000 RCF for 2 h. The EVs were then resuspended in 1X
PBS and stored at -80◦C, and hereafter are referred to as
cell culture EVs.
Particle Size Characterization
EV samples were analyzed with tunable resistive pulse sensing
(qNano, Izon Science Ltd, Christchurch, NZ) using a NP150
nanopore membrane at a 47 mm stretch. The concentration of
particles was standardized using multi-pressure calibration with
110 nm carboxylated polystyrene beads at a concentration of 1.2
× 1013 particles/mL.
Electrophoretic Analysis of DNA and
Proteins
DNA base-pair distribution and protein contamination were
analyzed on a 2100 Bioanalyzer (Agilent Technologies,
Santa Clara, CA, United States) using High Sensitivity
DNA and Protein 230 kits, respectively, according to the
manufacturer’s instructions.
Scanning Electron Microscopy
Following sample capture, the ACE chip was washed with
molecular grade water and frozen at -80◦C for 48 h. Immediately
before imaging, the chip was coated with 1 nm iridium using
an Emitech K575x Sputter Coater (Quorum Technologies, Kent,
United Kingdom). Scanning electron microscope images were
acquired using a FEI Quant FEG 250 (Thermo Fisher Scientific).
Acquisition settings are shown on the bottom banner of each
image presented.
Silica Column-Based Isolation of
Cell-Free DNA
DNA from the AsPC-1 cell culture EVs and one cancer donor
sample was isolated using the QIAamp Circulating Nucleic Acid
Kit (Qiagen N.V., Hilden, Germany), further referred to as QNA,
according to the manufacturer’s instructions from 120 µL sample
input and isolated into 50 µL of buffer AVE.
RESULTS
Simultaneous Capture and Detection of
DNA, RNA, and EV-Associated Protein
Biomarkers From Lung Cancer Donor
Plasma With the ACE Chip
The capability of the Verita platform to simultaneously isolate
cfDNA, exosomal RNA (exoRNA), and exosomal protein in
plasma was evaluated using fluorescent imaging. Biomarker
capture and on-chip detection of the biomarkers was performed
in plasma samples collected from two donors diagnosed with
Non-Small Cell Lung Cancer (NSCLC). Fluorescent dyes and
antibody specific for CD63 revealed a pattern consistent with the
capture of cfDNA, exoRNA, and EV-associated proteins over the
circular electrodes as shown in Figure 3.
The capability of the Verita platform to capture DNA from
diverse specimen types (blood, serum, plasma, and cerebrospinal
fluid) was investigated by spiking 50 pg/µL gDNA into each
solution and running the detection workflow. Fluorescent
signals detected on the ACE chip indicated the presence of
DNA following capture from all four solutions tested (see
Supplementary Figure S2). Previously published data showed
that the fluorescent intensity is proportional to the input DNA
concentration (Krishnan et al., 2011; Turner et al., 2018) and
demonstrates the utility of our platform for physiologically
relevant cfDNA concentrations in cancer patient plasma (Wu
et al., 2002; Volik et al., 2016).
Characteristics of DNA Isolated by the ACE Chip on
the Verita Platform
To examine the size selectivity of the cfDNA capture, several size
fractions of NoLimits DNA were spiked into K2EDTA plasma and
captured on and isolated from the chip. Capillary electrophoresis
was performed to determine the size distribution of DNA both
before capture and following isolation. Results revealed that
DNA >500 bp exhibited similar relative peaks both before
(Figure 4A) and after ACE capture and isolation (Figure 4B).
However, the 300 bp pre-capture peak was reduced in size, and
the 150 bp fragments were largely absent from the isolated DNA.
This result shows that the size selectivity of the chip can be biased
toward capture of cfDNA longer than 300 bp.
To verify that spiked NoLimits DNA accurately reflected
the behavior of endogenous cfDNA, patient donor plasma was
isolated using the QNA kit and compared to direct isolation for
the ACE chip. The isolated DNA from the QNA kit (Figure 4C)
exhibited both high and low molecular weight peaks with the
lower molecular weight peak representing the 160–180 bp DNA
fragments commonly associated with apoptotic DNA (Sunami
et al., 2008; Marzese et al., 2013; Zonta et al., 2015). Capillary
electrophoresis analysis of the cfDNA following isolation using
the chip demonstrated selection for large base pair fragments
similar to the NoLimits DNA (Figure 4D). These results indicate
that the ACE chip selectively isolates long cell-free DNA (>300
bp) from plasma samples.
The ability to analyze ACE isolated cfDNA by downstream
technologies, such as PCR and NGS, was evaluated using cell
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FIGURE 3 | Simultaneous isolation and detection of nucleic acids (cfDNA, exoRNA) and EV-associated protein biomarkers from lung cancer donor plasma.
Fluorescence imaging of chips to detect cfDNA (YOYO-1; left panels), exosomal RNA (SYTO RNAselect; middle panels), and exosome-associated proteins
(anti-CD63 antibodies; right panels) following isolation from two NSCLC K2EDTA donor plasma samples (Donor 635 top, Donor 6877 bottom) onto the ACE chip.
A B
C D
FIGURE 4 | ACE chips can preferentially isolate long cell-free DNA fragments. Capillary electrophoresis profiles for analysis of DNA size in eluates before and after
ACE chip capture. (A) Profile of 1× TE spiked with NoLimits DNA. (B) Profile of K2EDTA plasma spiked with NoLimits DNA after ACE chip capture and isolation.
Endogenous DNA profiles using a lung cancer donor K2EDTA plasma sample (Donor 9488) (C) Before isolation, (D) After isolation.
culture EVs from the AsPC-1 cell line, known to carry the
KRAS G12D point mutation, as a model system (Bamford
et al., 2004; Deer et al., 2010). The cell culture EVs were
spiked into K2EDTA plasma at a volumetric ratio of 1:10, with
DNA isolated using the ACE chip isolation workflow and the
QNA workflow. qPCR amplification plots were positive for the
presence of the KRAS G12D mutation using DNA isolated by
both methods. In addition, the housekeeping gene ACTB was
amplified from samples isolated using both methods, confirming
the feasibility of the ACE chip DNA isolation workflow for PCR
analysis (Figure 5A).
To characterize if the ACE chip captures a broad range of DNA
sequences, NGS was performed following ACE isolation of the
HD701 DNA quantitative reference standard, with variant allele
frequency (VAF) values detected that matched the expected VAFs
(Figure 5B). NGS was also used to analyze DNA from the AsPC-
1 cell culture EVs using the ACE chip. Single nucleotide variants
for KRAS G12D, FBXW7 R465C as well as the frameshift TP53
C135fs∗35 were reproducibly detected from the prepared libraries
(Figure 5C). These variants are known to be present in this cell
line’s genome (Deer et al., 2010) and in the cell culture EVs.
To verify that similar results are observed when using clinical
samples, DNA was isolated using the ACE chip from a lung
cancer donor that had previously been characterized by solid
tissue biopsy for the point mutations KRAS G12C and TP53
H193Y. Following sequencing, both mutations were reproducibly
detected using ACE isolated DNA (Figure 5D). Furthermore,
the germline mutation TP53 P72R was also detected on this
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FIGURE 5 | ACE-captured and isolated DNA can be amplified using PCR and NGS. (A) qPCR amplification profiles for the KRAS G12D mutation and ACTB
housekeeping gene using DNA isolated from AsPC-1 cell culture EVs using either the ACE chip or the QIAamp Circulating Nucleic Acid Kit (QNA). (B) Variant allele
frequency detected in the HD701 quantitative multiplex reference DNA standard after ACE isolation, compared to the expected frequency. (C) Variant allele
frequency shown for FBXW7, KRAS, and TP53 mutations in DNA captured from AsPC-1 cell culture EVs. (D) Variant allele frequency shown for TP53 and KRAS
point mutations in DNA captured from a lung cancer donor plasma sample (Donor 5734). Each replicate indicates an isolation from one chip and the subsequent
creation of one NGS library.
sample. These results demonstrate that DNA isolated by the
ACE chip can be readily used for NGS library preparation and
PCR amplification.
ACE Chip Platform Isolates EVs Containing Intact
RNA
The detection of CD63-positive material collected by the ACE
chip electrodes (Figure 3) suggested that EVs had been captured
on the edge of the electrodes. To further validate the capture of
EVs, a luminal EV-associated protein, TSG101, was examined
along with the membrane protein CD63, as recommended
by ISEV (Théry et al., 2018), using cell culture EVs from
MDA-MB-231 and AsPC-1 cell lines. Cell culture EVs were
spiked into K2EDTA plasma at a volumetric ratio of 1:10 and
captured using the detection workflow. Additionally, K2EDTA
plasma without EV spike was tested using the visualization
workflow. Intact membranes block access of antibodies to
luminal proteins. To overcome this limitation, EV membranes
were permeabilized with a 0.1% saponin solution prior to TSG101
antibody incubation. All three samples demonstrated positive
staining for both CD63 and TSG101 (Figure 6A). While the
samples with EV spikes demonstrated high florescent intensity
for both markers, the non-contrived K2EDTA plasma sample
yielded uniformly positive faint signal, likely due to lesser amount
of EVs.
To test the ability of the Verita platform to capture and detect
EV-associated cancer biomarkers directly from donor plasma,
lung cancer and pancreatic cancer donor plasma was subjected
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FIGURE 6 | ACE chip enables isolation of EVs and detection of EV-associated protein biomarkers. (A) Fluorescence images of the EV transmembrane biomarker
CD63 (green), and intra-vesicular biomarker TSG101 (red), following capture of cell culture EVs from the AsPC-1 (top), and MB-231 cell lines (middle) spiked into
K2EDTA plasma as well as K2EDTA plasma with no EVs spiked (bottom). (B) Particle sizing of EVs following ACE capture and isolation using NTA.
to the ACE detection workflow, and chips were stained with
antibodies for Program Death Ligand-1 (PD-L1) or Glypican 1
(GPC-1), respectively. Both sample types were positive for the
CD63 EV marker as well as the disease-related EV-associated
markers as shown in Figure 7A.
To characterize the size distribution of EVs captured by the
ACE chip, cell culture EVs from MDA-MB-231 and AsPC-1
cell lines were used as model systems. EVs were spiked at a
1:10 volumetric ratio into K2EDTA plasma and purified using
the ACE chip isolation workflow, followed by particle size
characterization. EVs isolated by the ACE chip exhibited a shift
in the distribution of mean particle size compared to pre-isolated
material for MDA-MB-231 (136–165 nm), while there was no
significant shift for the AsPC-1 EVs, as shown in Figure 6B and
Supplementary Figure S3. To test the ability of the ACE chip to
isolate EVs from donor samples, particle size characterization was
performed with eluates from lung cancer and melanoma donor
plasma samples (Figure 7B). Mean particle sizes were 164 and
147 nm, respectively, which reflected the size of EVs purified
from cell lines (range 136–165 nm) and implied the isolation of
intact EVs using the ACE chip. The EVs captured from the MDA-
MB-231 cell line were also examined with scanning electron
microscopy (SEM) as shown in Figure 8. Vesicles with a spherical
and/or peaked-spherical morphology, as previously noted (Ibsen
et al., 2017; Lewis et al., 2020), were observed to decorate both the
top and bottom of the electrode edges. The structures observed
are in the range of 100–200 nm in concordance with the particle
sizing measurements while the less-than perfect spherical form
may be attributed to protein aggregation around the vesicles.
EVs have been reported to contain diverse types of RNA,
and to protect the RNA from degradation by RNases (Rak and
Guha, 2012; Taylor and Gercel-Taylor, 2013; Enderle et al., 2015;
Zhang et al., 2015). Plasma samples were processed using the
ACE chip to isolate EVs, which were tested for the presence of
RNA using RT-PCR for the housekeeping mRNA gene PGK1.
Initially, AsPC-1 and MDA-MB-231 cell culture EVs were spiked
at a 1:10 volumetric ratio into K2EDTA plasma as well as
K2EDTA plasma without any spiked material. Isolates from both
spike and no spike experiments displayed strong signals in RT-
PCR (Ct = 30 and Ct = 31, for AsPC-1 and MDA-MB-231
derived EVs, respectively), with no spike control demonstrating
a weaker positive signal (Ct = 38.3), which likely represents
amplification of RNA from endogenous EVs (Figure 9A).
Additionally, EVs isolated from six lung cancer donor samples
and one melanoma donor sample were tested by RT-PCR,
and all showed positive amplification, whereas the no-template
control showed no amplification up to 45 cycles (Figure 9B).
Amplification performed with PGK1 exon-spanning primer pairs
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A B
FIGURE 7 | ACE chip enables capture of EVs and detection of EV-associated protein biomarkers from cancer donor plasma samples. (A) EVs were captured using
the ACE chip from two lung cancer donor samples (Donor 635, top, and Donor 6877, bottom) and antibodies against immune checkpoint protein PD-L1 (A, right)
were used. EVs were eluted off the chip; EV capture was confirmed by CD-63 staining (A, left) and particle sizing (B).
FIGURE 8 | Exosomes remain intact following ACE capture. Scanning electron microscopy (SEM) images of captured cell culture EVS from MDA-MB-231 cells at
20,000× magnification (left), and 80,000× magnification (right). The scale bars correspond to 2 µm and 500 nm, respectively. White arrows point to the EV
structures and red arrow to the electrode edge.
failed to generate a product from gDNA, confirming that the
signal observed was not generated by contaminating gDNA (data
not shown). These data demonstrated that the ACE chip captured
EVs containing intact RNA can be probed using RT-PCR.
DISCUSSION
The escalating adoption of a precision medicine approach,
particularly for oncology applications, continues to push the
demand for improved isolation and detection workflows, both for
clinical and research discovery applications. This study focused
on evaluating applicability of the platform as an on-chip detection
tool and/or as a flexible isolation workflow to analyze the three
classes of biomarkers that are critical for precision medicine:
cell-free DNA, RNA, and exosomal proteins.
Cell-free DNA has gained recognition as an important cancer
molecular biomarker and its concentration levels appear to reflect
apoptotic and necrotic cell death as well as inflammatory and
vascularization processes within the tumor and the surrounding
tissues. Previous studies have demonstrated that elevated
cfDNA levels within the blood occur for cancers originating
from different tissues, including lung (Ulivi et al., 2013;
Bortolin et al., 2015; Szpechcinski et al., 2015), ovary (Kamat
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FIGURE 9 | Amplification of mRNA isolated from ACE-captured EVs. (A) RT-PCR amplification profiles for housekeeping mRNA gene PGK1 using ACE isolated
materials from K2EDTA plasma spiked with MDA-MB-231 cell culture EVs (green), AsPC-1 cell culture EVs (blue), and with no spike (gray). (B) RT-PCR for PGK1
from endogenous EVs captured from melanoma and lung cancer donor K2EDTA plasma samples.
et al., 2006; No et al., 2012), breast (Umetani et al., 2006;
Lehner et al., 2013; Cheng et al., 2017), and others (Bettegowda
et al., 2014; Mouliere et al., 2014). A fraction of the cfDNA
released into the blood stream is a product of non-programmed
cell death, e.g., necrosis, resulting in long circulating cfDNA
fragments that have been suggested to be elevated in solid
tumors (Marzese et al., 2013). The levels of long circulating
cfDNA can be used to monitor treatment response, tumor
progression, or discriminate healthy controls from benign or
cancerous conditions (Umetani et al., 2006; Agostini et al., 2011;
Pinzani et al., 2011; Zonta et al., 2015; Szpechcinski et al., 2016).
In this work, we demonstrated how the ACE-based method
preferentially selects and quantifies a fraction of DNA that is
greater than 300 bp. This offers potential to evaluate the impact
of biological processes on a fraction of cfDNA that is typically not
associated with apoptotic origin.
The ACE chip also produces purified DNA that is compatible
with downstream molecular analysis techniques such as PCR
and NGS. The DNA isolated from a quantitative reference
standard, HD701, produced VAF values in the expected range,
and cell culture EVs from the AsPC-1 cell line also displayed
known genomic variants. According to the literature, the FBXW7
R564C variant is heterozygous while the KRAS G12D and
TP53 c135fs∗35 variants are homozygous. While the VAF values
observed here were not exactly 50 and 100%, respectively, there is
a consistent trend in zygosity (∼40% VAF for FBXW7 and ∼80%
for KRAS and TP53). Other analysis techniques, such as digital
droplet PCR, may help validate this observation. Additionally,
variant alleles that were initially identified in a lung cancer tumor
tissue biopsy were selectively amplified from cfDNA isolated
by ACE from the corresponding plasma sample. Several studies
have previously suggested the possibility of detection, treatment
monitoring, and prognostics using cfDNA (Dawson et al., 2013;
Bronkhorst et al., 2019). The Verita platform may support these
efforts through both the measurement and isolation of cfDNA.
The significance of the selectivity toward long base-pair cfDNA
by the ACE chip is currently under investigation, and further
studies may elucidate the clinical relevance of this fraction of
the cfDNA population, as has been previously suggested by DNA
integrity index studies (Cheng et al., 2009; Catarino et al., 2012;
Madhavan et al., 2014).
EV studies represent a growing field of translational research
and development because of their capacity to act as biomarkers
for cancer progression, angiogenesis, immune suppression, and
potential therapeutic uses (Lo Cicero et al., 2015; Reclusa et al.,
2017; Castellanos-Rizaldos et al., 2019). Common EV markers
(CD63, TSG101) and disease-specific EV-associated proteins
(PD-L1, GPC-1) were readily detected following isolation by the
ACE chip from either spiked EV or donor cancer samples. The
detection workflow described here employed two simultaneous
markers imaged at two different fluorescent wavelengths, directly
from biological fluids, without sample preprocessing.
The isolation of EVs on the ACE chip was confirmed by
both SEM and particle size analyses following isolation. The
former method revealed semispherical bodies on the edge of the
electrodes with sizes from 100 to 200 nm while the latter method
showed the expected size distribution for EVs. Nevertheless,
the true size distribution of EVs in particular exosomes is still
in debate and is heavily influenced by the isolation method
used (ultracentrifugation, precipitation, and affinity capture)
(Cvjetkovic et al., 2014; Van Deun et al., 2014). The particle size
distribution for the MDA-MB-231 EVs shown here is similar
to that shown by other particle sizing studies (Jenjaroenpun
et al., 2013; Kowal et al., 2016), and it is minimally altered
following capture and isolation with the ACE chip, suggesting
that ACE does not disturb the physicochemical characteristics
of the EVs. When endogenous EVs from cancer donor samples
were isolated with the ACE chip, similar particle size distributions
were observed, confirming that the properties observed for the
control models can be extended to donor samples. Although most
of the size distribution is centered around 120 nm, there are
a few “peaks” at larger particle sizes >300 nm (Figure 8) that
may arise from microvesicles isolated on the ACE chip and/or
due to the fact that there is no plasma prefiltering prior to
running the isolation workflow, in contrast to other EV extraction
methodologies (Enderle et al., 2015).
RT-PCR of PGK1 mRNAs purified by ACE from both
spiked and endogenous plasma EVs generated the expected PCR
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products, suggesting that the quality of the ACE chip-isolated
material is sufficient for downstream transcriptomics. There is
a distinct difference between the amplification values from the
spiked EVs compared to the K2EDTA plasma without a spike.
The amplification observed for the non-spiked plasma is likely
due to the presence of endogenous EVs that are also isolated on
the ACE chip. Likewise, EVs isolated from cancer plasma donors
show positive amplification on RT-PCR. Interestingly, the RT-
PCR amplification was performed without prior RNA extraction
from the ACE chip-isolated EVs. It is likely that the ACE EV
isolation method reduced the level of contaminating proteins that
may interfere with the amplification process, as observed from
the Protein Bioanalyzer results (Supplementary Figure S4). This
may allow the reverse transcription process more access to the
RNA cargo compared to traditional EV isolation methods. In the
future, the ACE-based chip EV isolation method may facilitate
the use of EV-derived RNA to determine tissue of origin and other
clinical applications (Kalluri and LeBleu, 2020).
While this work was largely focused on cancer, it is important
to note that the ACE-based biomarker isolation platform is
disease-agnostic. The platform demonstrated its potential to
expand the discovery toolset—with the ability to simultaneously
investigate multiple classes of unprocessed biomarkers in
the same sample—potentially offering a more comprehensive
understanding of disease biology for the next generation of
personalized medicine spanning many therapeutic applications
beyond oncology.
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